

# William L Carroll

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923270/publications.pdf>

Version: 2024-02-01

355  
papers

21,765  
citations

10389

72  
h-index

10445

139  
g-index

357  
all docs

357  
docs citations

357  
times ranked

16546  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	7.2	14
2	Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia. <i>Haematologica</i> , 2022, 107, 1746-1757.	3.5	14
3	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	4.1	12
4	Outstanding outcomes in infants with <i>KMT2A</i> -germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	3.5	11
5	The new reality is virtual. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29774.	1.5	0
6	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.	1.6	0
7	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	1.4	3
8	Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28843.	1.5	78
9	Reply to A. K. Agrawal et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 695-696.	1.6	0
10	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed <i>KMT2A</i> -rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. <i>Leukemia</i> , 2021, 35, 1279-1290.	7.2	46
11	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	4.7	7
12	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions. <i>Cancers</i> , 2021, 13, 1847.	3.7	20
13	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131. <i>Journal of Clinical Oncology</i> , 2021, 39, 10004-10004.	1.6	3
14	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021, 39, 1437-1447.	1.6	56
15	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	1.6	19
16	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 10003-10003.	1.6	0
17	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. <i>Blood Advances</i> , 2021, 5, 2890-2900.	5.2	3
18	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29256.	1.5	10

#	ARTICLE	IF	CITATIONS
19	dMMR and thiopurines strand TP53 for ALL relapse. <i>Nature Cancer</i> , 2021, 2, 777-779.	13.2	1
20	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021, 138, 2382-2382.	1.4	0
21	Non-Classical Monocyte Abundance Is an Independent Adverse Risk Factor for Relapse in Pediatric B-ALL. <i>Blood</i> , 2021, 138, 1316-1316.	1.4	0
22	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2021, 138, 211-211.	1.4	3
23	From Favorable Histology to Relapse: The Clonal Evolution of a Wilms Tumor. <i>Pediatric and Developmental Pathology</i> , 2020, 23, 167-171.	1.0	2
24	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. <i>Leukemia</i> , 2020, 34, 1006-1016.	7.2	8
25	<i>ARID5B</i> Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 256-264.	7.0	25
26	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020, 38, 602-612.	1.6	107
27	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. <i>Cancer Research</i> , 2020, 80, 5189-5202.	0.9	9
28	Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. <i>Paediatric Drugs</i> , 2020, 22, 485-499.	3.1	21
29	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	1.6	136
30	Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28306.	1.5	5
31	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. <i>Molecular Cancer Research</i> , 2020, 18, 1153-1165.	3.4	20
32	Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2020, 37, 867-882.e12.	16.8	108
33	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	1.6	41
34	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. <i>Haematologica</i> , 2020, 106, 46-55.	3.5	29
35	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 1897-1905.	1.6	117
36	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. <i>Blood</i> , 2020, 136, 20-21.	1.4	5

#	ARTICLE	IF	CITATIONS
37	Integrin $\alpha 6$ mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , 2020, 136, 210-223.	1.4	31
38	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report. <i>Journal of Clinical Oncology</i> , 2020, 38, 10510-10510.	1.6	7
39	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932. <i>Journal of Clinical Oncology</i> , 2020, 38, 10509-10509.	1.6	3
40	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 38-39.	1.4	0
41	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.4	32
42	Immune-Based Therapies in Acute Leukemia. <i>Trends in Cancer</i> , 2019, 5, 604-618.	7.4	32
43	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019, 60, 1740-1748.	1.3	25
44	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	3.5	11
45	Targeting a major hub of cell fate decisions – the mitochondrial-associated membrane. <i>Haematologica</i> , 2019, 104, 419-421.	3.5	1
46	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	1.5	8
47	Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 186, 274-285.	2.5	65
48	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 780-789.	1.6	48
49	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. <i>Blood Advances</i> , 2019, 3, 1647-1656.	5.2	17
50	Mechanisms of <i>NT5C2</i> -Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1887-1895.	4.1	17
51	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	3.5	25
52	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	21.4	384
53	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. <i>Blood</i> , 2019, 134, 1293-1293.	1.4	4
54	Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Children's Oncology Group (COG). <i>Journal of Clinical Oncology</i> , 2019, 37, 10005-10005.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. <i>Journal of Clinical Oncology</i> , 2019, 37, 10008-10008.	1.6	31
56	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 649-649.	1.4	5
57	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018, 32, 1370-1379.	7.2	40
58	Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. <i>Leukemia</i> , 2018, 32, 1393-1403.	7.2	27
59	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. <i>Cancer Medicine</i> , 2018, 7, 3-12.	2.8	13
60	The ASPHO 2018 Distinguished Career Award goes to Dr. Michael P. Link. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26987.	1.5	0
61	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018, 124, 1150-1159.	4.1	46
62	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018, 131, 1350-1359.	1.4	158
63	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	1.4	170
64	MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. <i>Haematologica</i> , 2018, 103, 830-839.	3.5	35
65	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. <i>Cancer</i> , 2018, 124, 571-579.	4.1	31
66	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	1.6	185
67	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	1.6	121
68	The potential of precision medicine for childhood acute lymphoblastic leukemia: opportunities and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 343-356.	0.7	1
69	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	1.6	164
70	NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. <i>Leukemia</i> , 2018, 32, 2527-2535.	7.2	13
71	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018, 132, 815-824.	1.4	97
72	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018, 132, 1000-1000.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	1.4	7
74	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10500-10500.	1.6	54
75	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	1.4	14
76	The NSD2 p.E1099K Mutation in Relapse Pediatric Acute Lymphoblastic Leukemia Is Linked to Mercaptopurine Resistance. <i>Blood</i> , 2018, 132, 3962-3962.	1.4	0
77	NSD2 Mutations in Pediatric ALL Leads to a Distinct Gene Expression Profile and Epigenetic Landscape That Is Cell Context Specific. <i>Blood</i> , 2018, 132, 3905-3905.	1.4	0
78	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018, 132, 659-659.	1.4	0
79	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. <i>Blood</i> , 2017, 129, 1919-1926.	1.4	32
80	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	1.4	236
81	Beating the Clock in T-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 873-875.	7.0	7
82	New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 725-736.	2.4	34
83	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	21.4	693
84	Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 843-846.	2.5	4
85	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2700-2707.	1.6	38
86	Reply to I.J. Cohen. <i>Journal of Clinical Oncology</i> , 2017, 35, 3989-3991.	1.6	2
87	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. <i>Journal of Clinical Oncology</i> , 2017, 35, 1730-1736.	1.6	26
88	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	1.6	64
89	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10514-10514.	1.6	0
90	Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 255-261.	1.5	17

#	ARTICLE	IF	CITATIONS
91	Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, e21-e25.	0.6	8
92	Therapies on the horizon for childhood acute lymphoblastic leukemia. <i>Current Opinion in Pediatrics</i> , 2016, 28, 12-18.	2.0	16
93	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 409-417.	0.6	9
94	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	1.6	301
95	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2133-2140.	1.6	88
96	Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. <i>Cancer</i> , 2016, 122, 1608-1617.	4.1	69
97	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <scp>AALL0331</scp>. <i>International Journal of Cancer</i> , 2016, 138, 332-339.	5.1	66
98	Progress and Prospects in Pediatric Leukemia. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2016, 46, 229-241.	1.7	50
99	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup. <i>Cancer</i> , 2016, 122, 1116-1125.	4.1	72
100	Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. <i>ACS Chemical Biology</i> , 2016, 11, 1305-1312.	3.4	128
101	Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. <i>Leukemia and Lymphoma</i> , 2016, 57, 1938-1941.	1.3	26
102	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016, 128, 1086-1086.	1.4	2
103	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. <i>Blood</i> , 2016, 128, 3965-3965.	1.4	5
104	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 451-451.	1.4	4
105	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	1.4	1
106	Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG <i>E. coli</i> L-asparaginase): Results from Children's Oncology Group (COG) study AALL07P4.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10508-10508.	1.6	3
107	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. <i>Blood</i> , 2016, 128, 4083-4083.	1.4	0
108	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 759-759.	1.4	0
110	Using Whole Exome Sequencing in Pediatric Acute Lymphoblastic Leukemia Germline, Diagnosis, and Relapse Trios to Discover Novel Relapse Enriched Mutations for Clonal Backtracking By Ddpcr. <i>Blood</i> , 2016, 128, 4085-4085.	1.4	0
111	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 907-907.	1.4	0
112	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 455-455.	1.4	1
113	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. <i>Blood</i> , 2016, 128, 1739-1739.	1.4	0
114	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 414-418.	1.5	31
115	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015, 125, 680-686.	1.4	110
116	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	1.4	287
117	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , 2015, 126, 2202-2212.	1.4	88
118	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1770-1776.	1.4	102
119	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1171-1175.	1.5	89
120	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	1.5	76
121	State of the Art Discovery with Tumor Profiling in Pediatric Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e601-e607.	3.8	4
122	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 287.	7.1	114
123	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	1.4	64
124	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 815.	7.4	234
125	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015, 6, 6604.	12.8	281
126	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015, 47, 607-614.	21.4	126





#	ARTICLE	IF	CITATIONS
145	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	1.6	91
146	Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 87-99.	2.5	61
147	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	27.0	1,161
148	Ikars deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1779-1785.	1.5	23
149	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. <i>Blood</i> , 2014, 123, 2017-2025.	1.4	109
150	Refining prognosis in BCR-ABL1â€“positive ALL. <i>Blood</i> , 2014, 123, 1626-1627.	1.4	3
151	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014, 124, 1266-1276.	1.4	84
152	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 1-1.	1.4	113
153	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 3649-3649.	1.4	5
154	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014, 124, 367-367.	1.4	1
155	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. <i>Blood</i> , 2014, 124, 684-684.	1.4	4
156	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. <i>Blood</i> , 2014, 124, 791-791.	1.4	28
157	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014, 124, 793-793.	1.4	15
158	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) study AALL03N1.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10013-10013.	1.6	2
159	The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) protocol AALL0433.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10014-10014.	1.6	3
160	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) Studies AALL0331 and AALL0232.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10016-10016.	1.6	1
161	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 612-612.	1.4	0
162	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	1.4	6

#	ARTICLE	IF	CITATIONS
163	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Blood</i> , 2014, 124, 132-132.	1.4	1
164	MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL. <i>Blood</i> , 2014, 124, 789-789.	1.4	0
165	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 792-792.	1.4	0
166	Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 210-210.	1.4	0
167	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2014, 124, 369-369.	1.4	0
168	Screening for gene mutations: will identification of <i>NT5C2</i> mutations help predict the chance of relapse in acute lymphoblastic leukemia?. <i>Expert Review of Hematology</i> , 2013, 6, 223-224.	2.2	8
169	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 148-155.	1.4	61
170	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , 2013, 19, 1014-1022.	30.7	100
171	<i>HMGA1</i> overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2565-2567.	1.3	27
172	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. <i>Blood</i> , 2013, 121, 485-488.	1.4	156
173	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 957-963.	1.5	149
174	Relapse-specific mutations in <i>NT5C2</i> in childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 290-294.	21.4	264
175	Inherited <i>GATA3</i> variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	21.4	264
176	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 733-742.	6.3	208
177	Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 3397-3402.	1.6	125
178	Safety in numbers: hyperdiploidy and prognosis. <i>Blood</i> , 2013, 121, 2374-2376.	1.4	11
179	Inhibition Of The Wnt Pathway Leads To Improved Chemosensitivity In Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1428-1428.	1.4	8
180	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 232-232.	1.4	8

#	ARTICLE	IF	CITATIONS
181	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	1.4	35
182	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2013, 122, 59-59.	1.4	5
183	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 60-60.	1.4	1
184	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 618-618.	1.4	6
185	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 824-824.	1.4	4
186	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013, 122, 825-825.	1.4	8
187	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€œ or â€œBCR-ABL1-Likeâ€œ) Signature For Therapeutic Targeting and Clinical Intervention. <i>Blood</i> , 2013, 122, 826-826.	1.4	65
188	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. <i>Blood</i> , 2013, 122, 837-837.	1.4	13
189	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10001-10001.	1.6	4
190	Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Children's Oncology Group (COG) study AALL0331.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10002-10002.	1.6	1
191	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3868-3868.	1.4	0
192	Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway In Glucocorticoid Resistance In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1296-1296.	1.4	0
193	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. <i>Blood</i> , 2013, 122, 229-229.	1.4	0
194	Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 602-602.	1.4	1
195	<i>ARID5B</i> Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 751-757.	1.6	165
196	Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2753-2759.	1.6	82
197	Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. <i>Blood</i> , 2012, 119, 817-825.	1.4	80
198	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2012, 119, 1872-1881.	1.4	110

#	ARTICLE	IF	CITATIONS
199	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. <i>Blood</i> , 2012, 119, 3512-3522.	1.4	210
200	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 153-166.	16.8	621
201	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 5201-5210.	1.4	123
202	Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1663-1669.	1.6	944
203	Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. <i>Pediatric Blood and Cancer</i> , 2012, 59, 834-839.	1.5	29
204	Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2012, 160, 10-18.	1.8	41
205	Imatinib resistant <i>BCR</i> $\rightarrow$ <i>ABL1</i> mutations at relapse in children with <i>P</i> <sup>h</sup> <i>+</i> <i>ALL</i> : a <i>C</i> hildren's <i>O</i> ncology <i>G</i> roup ( <i>COG</i> ) study. <i>British Journal of Haematology</i> , 2012, 157, 507-510.	2.5	36
206	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012, 120, 137-137.	1.4	7
207	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. <i>Blood</i> , 2012, 120, 2529-2529.	1.4	10
208	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. <i>Blood</i> , 2012, 120, 470-470.	1.4	4
209	Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2012, 120, 665-665.	1.4	3
210	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2012, 120, 882-882.	1.4	2
211	Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9548-9548.	1.6	2
212	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group study AALL0232.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA9508-CRA9508.	1.6	6
213	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group study AALL0232.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA9508-CRA9508.	1.6	0
214	Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG <i>e. coli</i> <i>L</i> -asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9543-9543.	1.6	1
215	Relapse-specific mutations in cytosolic 5' $\rightarrow$ 3' nucleotidase II in childhood acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9507-9507.	1.6	0
216	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. <i>Blood</i> , 2012, 120, 1300-1300.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood, 2012, 120, 2563-2563.	1.4	0
218	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 530-530.	1.4	3
219	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Blood, 2012, 120, 877-877.	1.4	2
220	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. Blood, 2012, 120, 776-776.	1.4	0
221	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood, 2012, 120, 291-291.	1.4	5
222	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. Blood, 2012, 120, 289-289.	1.4	4
223	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study. Blood, 2012, 120, 2505-2505.	1.4	0
224	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia. Blood, 2012, 120, 2565-2565.	1.4	0
225	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. Blood, 2012, 120, 528-528.	1.4	17
226	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood, 2011, 117, 3010-3015.	1.4	67
227	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2011, 118, 243-251.	1.4	126
228	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood, 2011, 118, 5218-5226.	1.4	180
229	Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood, 2011, 118, 6043-6049.	1.4	118
230	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	21.4	239
231	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. Pediatric Blood and Cancer, 2011, 57, 569-577.	1.5	55
232	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. Blood, 2011, 118, 1440-1440.	1.4	3
233	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. Blood, 2011, 118, 1510-1510.	1.4	12
234	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. Blood, 2011, 118, 573-573.	1.4	21

#	ARTICLE	IF	CITATIONS
235	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. <i>Blood</i> , 2011, 118, 743-743.	1.4	3
236	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. <i>Blood</i> , 2011, 118, 837-837.	1.4	1
237	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. <i>Blood</i> , 2011, 118, 739-739.	1.4	2
238	Epigenetic Modulation Leads to Re-Expression of Relapse Specific Silenced Genes and Induces Chemosensitivity in Childhood Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011, 118, 3455-3455.	1.4	0
239	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. <i>Pediatric Blood and Cancer</i> , 2010, 54, 872-878.	1.5	22
240	Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. <i>Journal of Clinical Oncology</i> , 2010, 28, 4755-4761.	1.6	203
241	Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 1394-1405.	1.4	192
242	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 5312-5321.	1.4	503
243	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. <i>Blood</i> , 2010, 116, 2752-2752.	1.4	7
244	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclox Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclox IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. <i>Blood</i> , 2010, 116, 2757-2757.	1.4	1
245	Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991. <i>Blood</i> , 2010, 116, 497-497.	1.4	1
246	Early Response Characteristics and Blast Cytogenetic Features In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. <i>Blood</i> , 2010, 116, 414-414.	1.4	0
247	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 8-8.	1.4	1
248	Administration of Erwinia Asparaginase (Erwinase®) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). <i>Blood</i> , 2010, 116, 2134-2134.	1.4	3
249	Vorinostat Reverses Relapse-Specific Drug Resistance Gene Expression Signatures In Childhood Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010, 116, 3630-3630.	1.4	1
250	Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 866-866.	1.4	0
251	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (< 90 Days vs. > 90 Days): A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 412-412.	1.4	0
252	High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL) Identifies Relapse Specific Mutations and Expression. <i>Blood</i> , 2010, 116, 3233-3233.	1.4	0

#	ARTICLE	IF	CITATIONS
253	JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9414-9418.	7.1	516
254	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	7.4	193
255	Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Review of Hematology, 2009, 2, 145-158.	2.2	28
256	Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 5175-5181.	1.6	643
257	Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1001-1005.	21.4	459
258	Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1243-1246.	21.4	559
259	Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2009, 360, 470-480.	27.0	1,260
260	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7
261	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. Blood, 2009, 114, 2389-2389.	1.4	1
262	AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. Blood, 2009, 114, 3076-3076.	1.4	4
263	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study.. Blood, 2009, 114, 3091-3091.	1.4	4
264	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. Blood, 2009, 114, 320-320.	1.4	1
265	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. Blood, 2009, 114, 704-704.	1.4	15
266	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. Blood, 2009, 114, 85-85.	1.4	10
267	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction: A Children's Oncology Group (COG) Study.. Blood, 2009, 114, 9-9.	1.4	24
268	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. Blood, 2009, 114, 907-907.	1.4	5
269	Up-Regulation of Genes Involved in Folate Metabolism Characterize Late but Not Early Relapse in Childhood Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 1733-1733.	1.4	0
270	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. Blood, 2009, 114, 2606-2606.	1.4	2



#	ARTICLE	IF	CITATIONS
271	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. Blood, 2009, 114, 2634-2634.	1.4	0
272	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. Blood, 2009, 114, 2598-2598.	1.4	6
273	“When can I go home?” seeking ways to lower the burden on patients and families. Pediatric Blood and Cancer, 2008, 51, 318-319.	1.5	0
274	Biology and Treatment of Acute Lymphoblastic Leukemia. Pediatric Clinics of North America, 2008, 55, 1-20.	1.8	86
275	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. Journal of Clinical Oncology, 2008, 26, 3756-3762.	1.6	211
276	Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 3971-3978.	1.6	210
277	Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 4376-4384.	1.6	102
278	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 2008, 111, 5477-5485.	1.4	751
279	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183.	1.4	179
280	Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia. Blood, 2008, 112, 2925-2925.	1.4	7
281	Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children's Oncology Group (COG).. Blood, 2008, 112, 898-898.	1.4	19
282	Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children's Oncology Group Study 1991. Blood, 2008, 112, 9-9.	1.4	12
283	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031.. Blood, 2008, 112, 911-911.	1.4	1
284	Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children's Oncology Group Study 1991. Blood, 2008, 112, 701-701.	1.4	1
285	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood, 2008, 112, 14-14.	1.4	1
286	Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse.. Blood, 2008, 112, 3345-3345.	1.4	0
287	Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients.. Blood, 2008, 112, 1203-1203.	1.4	0
288	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children's Oncology Group (COG) Study.. Blood, 2008, 112, 2256-2256.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. <i>Blood</i> , 2008, 112, 568-568.	1.4	13
290	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children's Oncology Group Trials.. <i>Blood</i> , 2008, 112, 1514-1514.	1.4	0
291	Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 427-427.	1.4	0
292	Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children's Oncology Group (COG).. <i>Blood</i> , 2008, 112, 917-917.	1.4	0
293	End points to establish the efficacy of new agents in the treatment of acute leukemia. <i>Blood</i> , 2007, 109, 1810-1816.	1.4	83
294	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	1.4	413
295	Potential of Gene Expression Profiling in the Management of Childhood Acute Lymphoblastic Leukemia. <i>Paediatric Drugs</i> , 2007, 9, 149-156.	3.1	5
296	Genetic Studies of a Cluster of Acute Lymphoblastic Leukemia Cases in Churchill County, Nevada. <i>Environmental Health Perspectives</i> , 2007, 115, 158-164.	6.0	51
297	Genome-Wide Profiling of High-Risk Pediatric Acute Lymphoblastic Leukemia (ALL): The ALL Pilot Project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) Initiative.. <i>Blood</i> , 2007, 110, 229-229.	1.4	2
298	Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2007, 110, 4-4.	1.4	25
299	Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Children's Oncology Group Study (COG).. <i>Blood</i> , 2007, 110, 583-583.	1.4	2
300	Children with t(12;21)/TEL-AML1-Positive Acute Lymphoblastic Leukemia Exhibit a Distinct Germline Genomic Signature.. <i>Blood</i> , 2007, 110, 760-760.	1.4	1
301	Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group Study.. <i>Blood</i> , 2007, 110, 1422-1422.	1.4	0
302	Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group.. <i>Blood</i> , 2007, 110, 758-758.	1.4	0
303	Outcomes for B-Precursor Patients in Legacy Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report.. <i>Blood</i> , 2007, 110, 847-847.	1.4	11
304	Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group Study.. <i>Blood</i> , 2007, 110, 725-725.	1.4	0
305	Expression Profiling Identifies Novel Genetic Subgroups with Distinct Clinical Features and Outcome in High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia (B-ALL). A Children's Oncology Group Study.. <i>Blood</i> , 2007, 110, 1430-1430.	1.4	0
306	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2006, 107, 4961-4967.	1.4	154

#	ARTICLE	IF	CITATIONS
307	Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2006, 108, 711-717.	1.4	147
308	Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2006, 47, 130-140.	1.5	130
309	Childhood acute lymphoblastic leukemia in the age of genomics. <i>Pediatric Blood and Cancer</i> , 2006, 46, 570-578.	1.5	32
310	Eliminating a gold standard in childhood acute lymphoblastic leukemia?. <i>Pediatric Blood and Cancer</i> , 2006, 47, 242-244.	1.5	0
311	Experimental validation of simulation methods for bi-directional transmission properties at the daylighting performance level. <i>Energy and Buildings</i> , 2006, 38, 878-889.	6.7	56
312	Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1977-1986.	4.9	8
313	Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children's Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).. <i>Blood</i> , 2006, 108, 146-146.	1.4	11
314	Factors Influencing Survival after Relapse from Childhood ALL: A Children's Oncology Group Study.. <i>Blood</i> , 2006, 108, 1855-1855.	1.4	4
315	Nelarabine Can Be Safely Incorporated into an Intensive, Multiagent Chemotherapy Regimen for the Treatment of T-Cell Acute Lymphocytic Leukemia (ALL) in Children: A Report of the Children's Oncology Group (COG) AALL00P2 Protocol for T-Cell Leukemia.. <i>Blood</i> , 2006, 108, 1864-1864.	1.4	3
316	Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children's Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.. <i>Blood</i> , 2006, 108, 1865-1865.	1.4	18
317	Outcomes of Children with First Marrow Relapse: Results from Children's Oncology Group (COG) Study AALL01P2.. <i>Blood</i> , 2006, 108, 1871-1871.	1.4	3
318	Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2006, 108, 219-219.	1.4	5
319	Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL.. <i>Blood</i> , 2006, 108, 2272-2272.	1.4	4
320	Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2006, 108, 2585-2585.	1.4	2
321	Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children's Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.. <i>Blood</i> , 2006, 108, 283-283.	1.4	1
322	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse.. <i>Blood</i> , 2006, 108, 49-49.	1.4	2
323	Individualized therapy for childhood acute lymphoblastic leukemia. <i>Personalized Medicine</i> , 2005, 2, 349-361.	1.5	4
324	On target for advances in the treatment of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2005, 105, 438-439.	1.4	1

#	ARTICLE	IF	CITATIONS
325	Building better therapy for children with acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2005, 7, 289-291.	16.8	4
326	Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?. <i>Pediatric Blood and Cancer</i> , 2005, 45, 876-880.	1.5	24
327	A Gene Expression Classifier for Improved Risk Classification and Outcome Prediction in Pediatric Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 762-762.	1.4	1
328	Gene Expression Pathways That Distinguish Diagnosis and Relapse in Childhood Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2005, 106, 848-848.	1.4	0
329	Gene Signatures Predictive of Outcome in Higher Risk Childhood Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 1449-1449.	1.4	0
330	Childhood Leukemia – New Advances and Challenges. <i>New England Journal of Medicine</i> , 2004, 351, 601-603.	27.0	39
331	Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2. <i>Cancer</i> , 2004, 101, 2106-2115.	4.1	17
332	Minimal Residual Disease(MRD) in Childhood Acute Lymphoblastic Leukemia(ALL) in Relapse. A Children’s Oncology Group (COG) Study.. <i>Blood</i> , 2004, 104, 324-324.	1.4	3
333	Race and Outcome in Childhood Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2061.	7.4	15
334	The Nucleophosmin-Anaplastic Lymphoma Kinase Fusion Protein Induces c-Myc Expression in Pediatric Anaplastic Large Cell Lymphomas. <i>American Journal of Pathology</i> , 2002, 161, 875-883.	3.8	43
335	Identification of gene expression profiles that segregate patients with childhood leukemia. <i>Clinical Cancer Research</i> , 2002, 8, 3118-30.	7.0	67
336	GENE EXPRESSION PROFILING. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 911-930.	2.2	20
337	A Novel Intron Element Operates Posttranscriptionally To Regulate Human N-myc Expression. <i>Molecular and Cellular Biology</i> , 1999, 19, 155-163.	2.3	24
338	Definition of the Human N-myc Promoter Region during Development in a Transgenic Mouse Model. <i>Pediatric Research</i> , 1999, 46, 255-262.	2.3	6
339	Somatic Hypermutation in T-Independent and T-Dependent Immune Responses toHaemophilus influenzaeType b Polysaccharide. <i>Clinical Immunology and Immunopathology</i> , 1998, 89, 240-246.	2.0	9
340	The Molecular Biology of Pediatric Lymphomas. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 282-296.	0.6	34
341	Expression of the c-Myc Protein in Childhood Medulloblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1998, 20, 18-25.	0.6	51
342	Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. <i>Oncogene</i> , 1997, 15, 1937-1946.	5.9	29

#	ARTICLE	IF	CITATIONS
343	The Absence of Ongoing Immunoglobulin Gene Hypermutation Suggests a Distinct Mechanism for c-myc Mutation in Endemic Burkitt's Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1996, 18, 29-35.	0.6	5
344	Analysis of hypermutation in immunoglobulin heavy chain passenger transgenes. <i>European Journal of Immunology</i> , 1996, 26, 1058-1062.	2.9	9
345	The Immunoglobulin Gene Repertoire to <i>Haemophilus influenzae</i> Type b. <i>Annals of the New York Academy of Sciences</i> , 1995, 764, 374-377.	3.8	1
346	Immunoglobulin Variable Region Usage in Human Intestinal B Lymphocytes. <i>Clinical Immunology and Immunopathology</i> , 1994, 71, 240-245.	2.0	10
347	Diversity of Immunoglobulin Light Chain Usage in the Human Immune Response to <i>Haemophilus influenzae</i> Type b Capsular Polysaccharide. <i>Pediatric Research</i> , 1993, 33, 307-311.	2.3	19
348	Development of the Human Antibody Repertoire. <i>Pediatric Research</i> , 1992, 32, 257-263.	2.3	30
349	c-myc Hypermutation in Burkitt's Lymphoma. <i>Leukemia and Lymphoma</i> , 1992, 8, 431-439.	1.3	31
350	A shuttle vector system for the investigation of immunoglobulin gene hypermutation: Absence of enhanced mutability in intermediate B cell lines. <i>Molecular Immunology</i> , 1992, 29, 1005-1011.	2.2	2
351	Hybridoma fusion cell lines contain an aberrant kappa transcript. <i>Molecular Immunology</i> , 1988, 25, 991-995.	2.2	121
352	Mouse-human heterohybridomas as fusion partners with human B cell tumors. <i>Journal of Immunological Methods</i> , 1986, 89, 61-72.	1.4	175
353	Pancytopenia with Myelofibrosis. <i>Clinical Pediatrics</i> , 1986, 25, 106-108.	0.8	13
354	Childhood bone marrow monosomy 7 syndrome: A familial disorder?. <i>Journal of Pediatrics</i> , 1985, 107, 578-580.	1.8	51
355	Selective Right Mainstem Bronchus Intubation as a Treatment for Persistent Left Pneumothorax in the Newborn. <i>Clinical Pediatrics</i> , 1983, 22, 450-452.	0.8	1